The firm, which expects to complete the move by June, said the new base will help meet growing drug industry demand for high-throughput analysis solutions like its RapidFire compound screening technology.
Biocius, which spun out from genome analysis group BioTrove following its acquisition by Life Technologies last year, also believes the new office and laboratory facility will improve how it works with customers.
CEO Jeffrey Leathe explained that new site “was designed with our clients in mind, our increased capacity includes state-of-the-art facilities for demonstration and training.”
The firm also said that the new space will “facilitate employee collaboration and represents the ideal environment for the team to address new technologies in the company’s development pipeline.”
Biocius growth has been rapid since it joined the discovery services market last year. The firm claims its technologies are used 13 of the top 15 pharma companies in Europe, the US and Canada.
And, more recently, Biocius entered the Asian pharmaceutical sector by partnering with Japanese distributor Wako Pure Chemical Industries.
Under that deal, signed earlier this month, Osaka-headquartered Wako will exclusively supply Biocius’ RapidFire system to the country’s pharmaceutical and biotechnology industry.
Wako will also supply other Biocius drug discovery and absorption, distribution, metabolism, and excretion (ADME) technologies, including the recently launched RF 300 system.
Speaking when the deal was announced Leathe said that: “Japan is an important market for pharmaceutical discovery and …we strongly believe that Wako is the right partner to provide our portfolio to this dynamic sector.”
Haruki Oishi, general manager of Wako’s biomedical systems department, was also positive about demand for Biocius’ technology in the country, particularly for challenging drug development projects.
"At Wako, we see a tremendous opportunity for RapidFire in Japan; we feel Biocius' technologies will enable us to provide our customers with drug discovery solutions through the synergy with Wako's product line and a means to investigate therapeutic targets that have been difficult to analyze by conventional methods."